Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 11Cancer Pain 11Pain 9Pain, Postoperative 5Agnosia 5Colorectal Neoplasms 3Colonic Neoplasms 3Neoplastic Cells, Circulating 2Neoplasm Metastasis 2Mucositis 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Inflammation 2Head and Neck Neoplasms 2Chronic Pain 2Breakthrough Pain 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Supratentorial Neoplasms 1Stomach Neoplasms 1Signs and Symptoms 1Sezary Syndrome 1Reperfusion Injury 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

relacorilant 1pembrolizumab 1glutathione pegylated liposomal doxorubicin 1ficlatuzumab 1bosutinib 1Trastuzumab 1Pemetrexed 1Morphine 1Methadone 1MRX-2843 1Imatinib Mesylate 1Cholecalciferol 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pathologic Processes × Morphine × Clear all
NCT04475029 2023-09-13

METAMORF

University of Aarhus

Phase NA Completed
114 enrolled
Genitourinary

Urinary Bladder Neoplasms, Neurologic Manifestations, Pain, Pain, Postoperative, Pathologic Processes, Postoperative Complications, Signs and Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡